Importance: Nonadherence to antidepressant medication is common and leads to poor outcomes. Early nonadherence is especially problematic. Objective: To test the effectiveness of a psychosocial intervention to improve early adherence among older patients whose primary care physician newly initiated an antidepressant for depression. Design, Setting, and Participants: The Treatment Initiation and Participation Program (TIP) was offered in a 2-site randomized clinical effectiveness study between January 2011 and December 2014 at primary care practices in New York, New York, and Ann Arbor, Michigan. Analyses began in February 2016. All participants were middle-aged and older adults (aged ≥55 years) who received newly initiated depression treatment by their primary care physician and recruited within 10 days of their prescription. Analyses were intention-to-treat. Interventions: Participants were randomly assigned to the intervention (TIP) or treatment as usual. Participants in the TIP group identified and addressed barriers to adherence, including stigma, misconceptions, and fears about treatment, before developing a personalized adherence strategy. The Treatment Initiation and Participation Program was delivered in three 30-minute contacts scheduled during a 6-week period just after the antidepressant was prescribed. Main Outcomes and Measures: The primary outcome was self-reported adherence on the Brief Medication Questionnaire, with adequate early adherence defined as taking 80% or more of the prescribed doses at 6 and 12 weeks. The secondary outcome was depression severity. Results: In total, 231 middle-aged and older adults (167 women [72.3%] and 64 men [27.7%]) without significant cognitive impairment were randomly assigned to the TIP intervention (n = 115) or treatment as usual (n = 116). Participants had a mean (SD) age of 67.3 (8.4) years. Participants in the TIP group were 5 times more likely to be adherent at 6 weeks (odds ratio, 5.54; 95% CI, 2.57 to 11.96; χ21 = 19.05; P < .001) and 3 times more likely to be adherent at both 6 and 12 weeks (odds ratio, 3.27; 95% CI, 1.73 to 6.17; χ21 = 13.34; P < .001). Participants in the TIP group showed a significant earlier reduction (24.9%) in depressive symptoms (95% CI, 13.9 to 35.9; t337 = 4.46; adjusted P < .001). In both groups, participants who were 80% adherent at weeks 6 and 12 had a 15% greater improvement in depressive symptoms from baseline over the course of treatment (95% CI, -0.2 to -30; t369 = 1.93; P = .051). Conclusions and Relevance: The Treatment Initiation and Participation Program is an effective intervention to improve early adherence to pharmacotherapy. Improved adherence can promote improvement in depression. Trial Registration: clinicaltrials.gov Identifier: NCT01301859.
RCT Entities:
Importance: Nonadherence to antidepressant medication is common and leads to poor outcomes. Early nonadherence is especially problematic. Objective: To test the effectiveness of a psychosocial intervention to improve early adherence among older patients whose primary care physician newly initiated an antidepressant for depression. Design, Setting, and Participants: The Treatment Initiation and Participation Program (TIP) was offered in a 2-site randomized clinical effectiveness study between January 2011 and December 2014 at primary care practices in New York, New York, and Ann Arbor, Michigan. Analyses began in February 2016. All participants were middle-aged and older adults (aged ≥55 years) who received newly initiated depression treatment by their primary care physician and recruited within 10 days of their prescription. Analyses were intention-to-treat. Interventions: Participants were randomly assigned to the intervention (TIP) or treatment as usual. Participants in the TIP group identified and addressed barriers to adherence, including stigma, misconceptions, and fears about treatment, before developing a personalized adherence strategy. The Treatment Initiation and Participation Program was delivered in three 30-minute contacts scheduled during a 6-week period just after the antidepressant was prescribed. Main Outcomes and Measures: The primary outcome was self-reported adherence on the Brief Medication Questionnaire, with adequate early adherence defined as taking 80% or more of the prescribed doses at 6 and 12 weeks. The secondary outcome was depression severity. Results: In total, 231 middle-aged and older adults (167 women [72.3%] and 64 men [27.7%]) without significant cognitive impairment were randomly assigned to the TIP intervention (n = 115) or treatment as usual (n = 116). Participants had a mean (SD) age of 67.3 (8.4) years. Participants in the TIP group were 5 times more likely to be adherent at 6 weeks (odds ratio, 5.54; 95% CI, 2.57 to 11.96; χ21 = 19.05; P < .001) and 3 times more likely to be adherent at both 6 and 12 weeks (odds ratio, 3.27; 95% CI, 1.73 to 6.17; χ21 = 13.34; P < .001). Participants in the TIP group showed a significant earlier reduction (24.9%) in depressive symptoms (95% CI, 13.9 to 35.9; t337 = 4.46; adjusted P < .001). In both groups, participants who were 80% adherent at weeks 6 and 12 had a 15% greater improvement in depressive symptoms from baseline over the course of treatment (95% CI, -0.2 to -30; t369 = 1.93; P = .051). Conclusions and Relevance: The Treatment Initiation and Participation Program is an effective intervention to improve early adherence to pharmacotherapy. Improved adherence can promote improvement in depression. Trial Registration: clinicaltrials.gov Identifier: NCT01301859.
Authors: Jo Anne Sirey; Anderson J Franklin; Sharon E McKenzie; Samiran Ghosh; Patrick J Raue Journal: Psychiatr Serv Date: 2014-04-01 Impact factor: 3.084
Authors: Michele R Spoont; David B Nelson; Maureen Murdoch; Thomas Rector; Nina A Sayer; Sean Nugent; Joseph Westermeyer Journal: Psychiatr Serv Date: 2014-05-01 Impact factor: 3.084
Authors: Amir Krivoy; Ran D Balicer; Becca Feldman; Moshe Hoshen; Gil Zalsman; Abraham Weizman; Gal Shoval Journal: J Clin Psychiatry Date: 2016-05 Impact factor: 4.384
Authors: Tara F Bishop; Patricia P Ramsay; Lawrence P Casalino; Yuhua Bao; Harold A Pincus; Stephen M Shortell Journal: Health Aff (Millwood) Date: 2016-03 Impact factor: 6.301
Authors: Marcia Valenstein; Hyungjin Myra Kim; Dara Ganoczy; John F McCarthy; Kara Zivin; Karen L Austin; Katherine Hoggatt; Daniel Eisenberg; John D Piette; Frederic C Blow; Mark Olfson Journal: J Affect Disord Date: 2008-10-22 Impact factor: 4.839
Authors: Gretchen A Brenes; Suzanne C Danhauer; Mary F Lyles; Patricia E Hogan; Michael E Miller Journal: Am J Geriatr Psychiatry Date: 2015-06-17 Impact factor: 4.105
Authors: Katarina Arandjelovic; Harris A Eyre; Eric Lenze; Ajeet B Singh; Michael Berk; Chad Bousman Journal: J Neural Transm (Vienna) Date: 2017-10-29 Impact factor: 3.575
Authors: Jo Anne Sirey; Alexandra Woods; Nili Solomonov; Lauren Evans; Samprit Banerjee; Paula Zanotti; George Alexopoulos; Helen C Kales Journal: Am J Geriatr Psychiatry Date: 2020-04-23 Impact factor: 4.105
Authors: Julio César Restrepo Zapata; Gloria Inés Martínez Dominguez; Lina María Martínez-Sánchez; María de Los Ángeles Rodríguez-Gázquez; Juan Ricardo Gaviria García; Andrea Urrego Vásquez; Juan Pablo Ospina-Sánchez; Natalia Morales Quintero; Felipe Hernández Restrepo; Sol Beatriz Ochoa Uribe Journal: Psychiatr Q Date: 2020-03
Authors: Alexandra Woods; Nili Solomonov; Brian Liles; Arielle Guillod; Helen C Kales; Jo Anne Sirey Journal: Am J Geriatr Psychiatry Date: 2021-01-05 Impact factor: 7.996